Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18618887 | ACTUATING MECHANISM FOR FLUID DISPLACEMENT AND PRESSURIZING DEVICES | March 2024 | April 2025 | Allow | 13 | 4 | 0 | No | No |
| 18488354 | Injector Device | October 2023 | August 2024 | Allow | 10 | 1 | 0 | No | No |
| 18199532 | Auto Injector With Improved Functionality | May 2023 | May 2024 | Allow | 12 | 1 | 0 | No | No |
| 17743959 | Rotary Motor Based Transdermal Injection Device | May 2022 | March 2025 | Allow | 34 | 1 | 0 | No | No |
| 17716603 | BOTULINUM TOXIN PREFILLED SYRINGE SYSTEM | April 2022 | June 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17761013 | Passive Safety Device, Injection Device Comprising the Same, and Method for Manufacturing Said Injection Device | March 2022 | August 2024 | Allow | 29 | 3 | 0 | Yes | No |
| 17588592 | INTRAVASCULAR CATHETER AND METHOD OF USE | January 2022 | February 2024 | Abandon | 25 | 4 | 0 | Yes | No |
| 17542096 | Passive Dilation in Catheter Insertion Systems | December 2021 | May 2025 | Allow | 41 | 5 | 1 | No | Yes |
| 17533859 | PEN NEEDLE EXCHANGE SYSTEM | November 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17527452 | METHOD OF ROBOTICALLY PERFORMING A NEUROVASCULAR PROCEDURE | November 2021 | October 2024 | Allow | 35 | 3 | 0 | Yes | No |
| 17602383 | INFUSION HEAD WITH CONTROLLED RELEASE OF SECONDARY DRUG | October 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17488744 | ACTUATING MECHANISM FOR FLUID DISPLACEMENT AND PRESSURIZING DEVICES | September 2021 | March 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17447751 | Multi-Function Syringe | September 2021 | November 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17464258 | INTRAVASCULAR OXYGENATION SYSTEM AND METHOD | September 2021 | March 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17462495 | INFUSION PUMP WITH TOGGLING CAPABILITY | August 2021 | March 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17297513 | SYRINGE SAFETY CAP AND SAFETY SYRINGE INCLUDING THE SAME | May 2021 | October 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17313901 | Enhanced Guide Wire Advancement Length | May 2021 | July 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17284554 | Seal | April 2021 | January 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17210685 | Alopecia Repair System | March 2021 | April 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17200566 | Guidewire-Management Devices and Methods Thereof | March 2021 | April 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17200630 | Guidewire-Management Devices and Methods Thereof | March 2021 | September 2024 | Allow | 42 | 3 | 1 | Yes | No |
| 17190001 | GUIDE WIRE INTRODUCER | March 2021 | October 2024 | Allow | 43 | 3 | 0 | No | No |
| 17187536 | Catheter with Optic Shape Sensing Capabilities | February 2021 | October 2024 | Allow | 44 | 4 | 0 | Yes | No |
| 17262676 | Injector | January 2021 | June 2025 | Allow | 53 | 5 | 0 | No | No |
| 17151385 | INFUSION DEVICE | January 2021 | November 2023 | Allow | 34 | 1 | 0 | Yes | No |
| 17253667 | TWO-CHAMBER TYPE COMBINED CONTAINER-SYRINGE | December 2020 | June 2025 | Allow | 54 | 5 | 0 | No | No |
| 17102958 | Rotary Motor Based Transdermal Injection Device | November 2020 | May 2024 | Allow | 42 | 0 | 0 | No | No |
| 17056702 | NEEDLE GUARD | November 2020 | April 2025 | Allow | 53 | 6 | 0 | Yes | No |
| 17056068 | NEEDLELESS PAIN-FREE INJECTION DEVICE | November 2020 | September 2023 | Allow | 34 | 2 | 0 | No | No |
| 17054478 | DEVICE AND METHOD FOR INJECTING LIQUID DRUG INTO NASAL CAVITY AND PARANASAL SINUSES | November 2020 | October 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17054377 | MALE CONNECTING DEVICE FOR MEDICAL USE | November 2020 | May 2024 | Allow | 42 | 2 | 0 | No | No |
| 17053993 | CONNECTING STRUCTURE FOR MEDICAL USE | November 2020 | September 2023 | Allow | 34 | 0 | 0 | No | No |
| 17086498 | ELECTROPORATION PROBE | November 2020 | October 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17085341 | DEVICE | October 2020 | March 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17250010 | SYSTEMS AND METHODS FOR SYRINGE HANDLING | October 2020 | September 2024 | Allow | 47 | 1 | 0 | Yes | No |
| 17079320 | Guidewire-Management Devices and Methods Thereof | October 2020 | August 2024 | Allow | 46 | 3 | 1 | No | No |
| 17049743 | IMPLANTABLE ULTRASOUND CONDUCTING AND DRUG DELIVERING APPARATUS | October 2020 | March 2025 | Abandon | 53 | 2 | 0 | No | No |
| 17077536 | INSUFFLATION DEVICE AND METHOD OF CONTROLLING INSUFFLATION DEVICE | October 2020 | March 2025 | Abandon | 52 | 2 | 0 | No | No |
| 16979636 | Dose Control Device for Injectable-Drug Delivery Devices | October 2020 | April 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17044962 | ELONGATED FUNCTIONAL SYSTEM CONFIGURED TO BE ADVANCED IN THE LUMEN OF A PIPE, A DUCT OR A TUBE | October 2020 | May 2025 | Abandon | 56 | 4 | 0 | No | No |
| 17043991 | Auto Injector With Improved Functionality | September 2020 | April 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 17031511 | INFUSION CATHETER AND METHODS OF USE | September 2020 | June 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17040439 | DEVICE FOR ADMINISTERING A FLUID | September 2020 | April 2024 | Allow | 43 | 2 | 0 | No | No |
| 17021773 | MRI SURGICAL SYSTEMS INCLUDING MRI-COMPATIBLE SURGICAL CANNULAS FOR TRANSFERRING A SUBSTANCE TO AND/OR FROM A PATIENT | September 2020 | January 2025 | Abandon | 52 | 3 | 0 | No | No |
| 16968954 | Injector Device | August 2020 | July 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 16966500 | PREFILLED SYRINGE AND METHOD OF STERILIZING A PREFILLED SYRINGE | July 2020 | May 2025 | Allow | 57 | 2 | 1 | No | No |
| 16601169 | FLUID DELIVERY DEVICE AND BONE SCREW | October 2019 | January 2025 | Allow | 60 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GRASMEDER, SARAH DYMPNA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GRASMEDER, SARAH DYMPNA works in Art Unit 3783 and has examined 46 patent applications in our dataset. With an allowance rate of 67.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner GRASMEDER, SARAH DYMPNA's allowance rate of 67.4% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GRASMEDER, SARAH DYMPNA receive 2.07 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by GRASMEDER, SARAH DYMPNA is 41 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +44.4% benefit to allowance rate for applications examined by GRASMEDER, SARAH DYMPNA. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 29.4% of applications are subsequently allowed. This success rate is in the 47% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 21.1% of cases where such amendments are filed. This entry rate is in the 19% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 99% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 99% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 43% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 42% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.